1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Janssen combats Harvoni competition with UK Olysio 'pay if you clear' scheme

 
• By Gemma Collier

Janssen has offered England and Scotland the chance to prescribe hepatitis C drug Olysio (simeprevir) on the National Health Service, and only pay for it in those patients who clear the virus within 12 weeks. Janssen's timing coincides with growing competition in the HCV space, and may be a way of fending off rivalry from Gilead's Harvoni (sofosbuvir and ledipasvir).

Janssen has offered England and Scotland the chance to prescribe hepatitis C drug Olysio (simeprevir) on the National Health Service, and only pay for it in those patients who clear the virus within 12 weeks. Janssen's timing coincides with growing competition in the HCV space, and may be a way of fending off rivalry from Gilead's Harvoni (sofosbuvir and ledipasvir).

As a way of managing the scheme, the company will fund pre-treatment blood tests for patients that can predict whether...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Prasad’s Exit From CBER Could Bode Well For Genetic Medicines

 
• By Jessica Merrill

Pharma companies like Sarepta, Replimune and Capricor made gains on Wall Street after news broke that the FDA Center for Biologics Evaluation and Research director Vinay Prasad is leaving.

Blenrep Questions Won’t Go Away But GSK Sees Chance To Lead In COPD

 
• By Andrew McConaghie

GSK is sticking to its guns on its forecasts for Blenrep and the firm’s total sales in 2031 despite concerns about the antibody-drug conjugate’s approvability in the US.

Lilly’s Jaypirca Threatens Imbruvica’s CLL Position After Phase III Results

 
• By Alaric DeArment

The BRUIN CLL-314 trial was designed to show noninferiority, but the p-value indicated a favorable result for Jaypirca in both the pre-treated and intent-to-treat populations.

CEO Underlines AstraZeneca’s Increasingly US-Centric Growth Plans

 
• By Andrew McConaghie

Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.

More from Therapy Areas

Novo Selects Internal CEO To Recharge Growth

 
• By Jessica Merrill

Maziar Mike Doustdar has led the company’s international operations and will succeed Lars Fruergaard Jørgensen on August 7.

Lilly’s Jaypirca Threatens Imbruvica’s CLL Position After Phase III Results

 
• By Alaric DeArment

The BRUIN CLL-314 trial was designed to show noninferiority, but the p-value indicated a favorable result for Jaypirca in both the pre-treated and intent-to-treat populations.

CEO Underlines AstraZeneca’s Increasingly US-Centric Growth Plans

 
• By Andrew McConaghie

Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.